ATE354361T1 - Neue verwendung von prodigiosin zur behandlung von diabetes mellitus - Google Patents

Neue verwendung von prodigiosin zur behandlung von diabetes mellitus

Info

Publication number
ATE354361T1
ATE354361T1 AT00952026T AT00952026T ATE354361T1 AT E354361 T1 ATE354361 T1 AT E354361T1 AT 00952026 T AT00952026 T AT 00952026T AT 00952026 T AT00952026 T AT 00952026T AT E354361 T1 ATE354361 T1 AT E354361T1
Authority
AT
Austria
Prior art keywords
prodigiosin
diabetes mellitus
treatment
new use
treat
Prior art date
Application number
AT00952026T
Other languages
English (en)
Inventor
Hwanmook Kim
Sangbae Han
Changwoo Lee
Kihoon Lee
Sehyung Park
Youngkook Kim
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Application granted granted Critical
Publication of ATE354361T1 publication Critical patent/ATE354361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00952026T 2000-02-15 2000-08-10 Neue verwendung von prodigiosin zur behandlung von diabetes mellitus ATE354361T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000007139A KR20010081515A (ko) 2000-02-15 2000-02-15 프로디지오신의 당뇨병 예방 및 치료용 조성물

Publications (1)

Publication Number Publication Date
ATE354361T1 true ATE354361T1 (de) 2007-03-15

Family

ID=19646694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00952026T ATE354361T1 (de) 2000-02-15 2000-08-10 Neue verwendung von prodigiosin zur behandlung von diabetes mellitus

Country Status (7)

Country Link
US (1) US6638968B1 (de)
EP (1) EP1251847B1 (de)
KR (2) KR20010081515A (de)
AT (1) ATE354361T1 (de)
AU (1) AU6479000A (de)
DE (1) DE60033569T2 (de)
WO (1) WO2001060361A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014987A1 (en) * 2000-01-26 2004-01-22 Gemin X Biotechnologies Inc. Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases
KR100392225B1 (ko) * 2001-04-19 2003-07-22 한국생명공학연구원 류머티스 관절염 치료용 프로디지오신 조성물
DE60223571T2 (de) * 2001-07-18 2008-07-24 Gemin X Pharmaceuticals Canada. Inc., Montreal Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktion
DE102013006341A1 (de) 2013-04-15 2014-10-16 Yoen Ok Roth Pharmazeutisches Erzeugnis zur Behandlung von Augenerkrankungen
US10870640B2 (en) 2016-04-08 2020-12-22 Institute For Cancer Research Prodigiosin analogs and methods of use
WO2017177216A1 (en) * 2016-04-08 2017-10-12 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Prodigiosin analogs
KR101995768B1 (ko) * 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326284D0 (en) * 1993-12-23 1994-02-23 Erba Carlo Spa Pyrrolydenemethyl-derivatives and process for their preparation
GB9603212D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Process for the preparation of 2,2'-bipyrrolyl-pyrromethane derivatives
KR100252197B1 (ko) * 1997-09-20 2000-04-15 박호군 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신
GB9802745D0 (en) * 1998-02-09 1998-04-08 Pharmacia & Upjohn Spa Benzyloxy prodigiosine compounds

Also Published As

Publication number Publication date
EP1251847B1 (de) 2007-02-21
AU6479000A (en) 2001-08-27
KR20010108108A (ko) 2001-12-07
EP1251847A4 (de) 2004-11-10
US6638968B1 (en) 2003-10-28
EP1251847A1 (de) 2002-10-30
WO2001060361A1 (en) 2001-08-23
DE60033569T2 (de) 2007-10-31
KR100406848B1 (ko) 2003-11-21
DE60033569D1 (de) 2007-04-05
KR20010081515A (ko) 2001-08-29

Similar Documents

Publication Publication Date Title
DE60101669D1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69526311D1 (de) Verwendung von Rapamycin zur Behandlung von Anämie
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE303147T1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE361755T1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE69504717D1 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties